Progesterone Receptors as a Prognostic Factor in Stage II Breast Cancer

Clark, Gary M.; McGuire, William; Hubay, Charles A.; Pearson, Olof H.; Marshall, James S.

doi:10.1056/nejm198312013092240

Cited by 340 publications

(110 citation statements)

References 5 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…Shortly, any hormone receptor positivity gives better prognosis for success of antihormonal therapy (29,30). We were not able to find any available published investigation of the prognostic impact of ER/PgR coexpression profiles on DSS and overall survival without relation to endocrine therapy.…”

Section: Discussionmentioning

confidence: 90%

Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas

Valkov

Sørbye²,

Kilvaer³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas

Valkov

Sørbye²,

Kilvaer³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…Newer evidence suggests that this approach may change. Retrospective studies suggest that PR positivity can be categorized into 3 groups (< 10, 10 to 60 and ≥60 fmol/mg), which can predict the response to adjuvant tamoxifen, and might also be the second most critical factor, equal or even of greater value that ER expression, in predicting DFS [25,26]. The combination of PR expression with Ki-67 seems to improve the accuracy of IHC-based classification of luminal A and luminal B breast cancer, especially for postmenopausal women [21].…”

Section: Discussionmentioning

confidence: 99%

Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01)

Agrawal

Banswal

Saha

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC), apart from increasing breast conservation rates, also provides an opportunity to assess tumour response to chemotherapy, with Pathological Complete Response (pCR) described as an independent prognostic factor and a surrogate marker for better outcome and survival. Our primary aim was to identify clinical and pathological factors associated with pCR following NACT in patients with LABC treated at our institution. Our secondary aim was to analyze the impact of pCR and associated factors on disease free survival (DFS) and overall survival (OS). A retrospective analysis of LABC patients treated with NACT between Jun 2011 and Dec 2013. Clinical and histological variables were analyzed for association with pCR (no invasive or in situ carcinoma in breast or axillary lymph nodes). Kaplan-Meier curves and Cox regression model was used for survival analysis. All values were twosided, and statistical significance was defined as p < 0.05. 240 patients were included. The median tumor size was 6 cm, with T4 disease in 49.8 %. 45 % of tumors were of low grade (G1 + G2) and 53.8 % of high grade (G3). Estrogen Receptor (ER) was positive in 70.8 %, progesterone receptor (PR) in 53.3 % and Her2 in 38.8 %. The preferred NACT regimen was sequential anthracycline and taxane and 88.8 % of patients received this regimen. Of 93 potential Her2 Positive patients, only 23 received trastuzumab. Overall 23.2 % patients had pCR. At median follow up of 21 months (range, 3-42), 16.3 % of patients had recurrent disease, and 6.7 % had died. High tumor grade (p = 0.04), PR negative status (p < 0.01) and trastuzumab treatment (p = 0.01) were significant predictors of pCR in univariate analysis. On multivariate analysis PR negativity (OR 3.2, 95 % CI = 1.6 to 6.04, p = 0.001) and Trastuzumab use (OR 0.24, 95 % CI = 0.1 to 0.6, p = 0.004) were significant. Patients with pCR had positive associations with survival (p < .02,OS& .02,DFS) and interestingly PR positivity had positive association with DFS (p = 0.02) in Kaplan-Meier curves. On Cox regression, PR positivity (HR = 0.3, p < 0.01) and pCR (HR = 0.2, p < 0.01) correlated with DFS, though not with early OS. for the PR positive patients were paradoxical. Though less likely to have pCR (15 %, vs 32 % if PR negative), they had better DFS (p = 0.02), and achieving pCR had no survival benefit in this group. In contrast, PR negative patients, irrespective of ER status, had a high pCR rate, and achieving pCR had survival advantage (p < 0.05,DFS& p < 0.02,OS). PR negative patients without pCR had the worst DFS (p < 0.01) among all. High grade and Trastuzumab treatment as predictors of pCR, and pCR as a surrogate marker for survival are well recognized, and are supported by our findings. In present cohort, PR negativity showed prognostic importance independent of ER status. However these results were derived from sub-group, posthoc analysis of data from a pre-existing cohort, without 'apriori' hypothesis for survival analy...

show abstract

“…Furthermore, the level of PR expression provides important clinical information as shown by Clark et al (1983). As the use of enzyme-linked immunosorbent assays (ELISA) and immunohistochemical assays for PR detection increases, it is likely that variant PR expression will interfere with these assays.…”

Section: Discussionmentioning

confidence: 99%

Altered expression of exon 6 deleted progesterone receptor variant mRNA between normal human breast and breast tumour tissues

et al. 1999

View full text Add to dashboard Cite

The progesterone receptor (PR) is an important prognostic marker in breast cancer as well as a marker of responsiveness to endocrine therapies. The presence of several exon-deleted PR variant mRNAs in both normal and neoplastic breast samples has recently been reported. Amongst them, a variant mRNA deleted in exon 6 (D6-PR mRNA) that if translated would encode a truncated PR-like protein missing the hormone binding domain and one of the transactivating domains of the wild-type PR protein. In order to determine whether changes in D6-PR variant expression could occur during tumorigenesis, its expression was investigated by reverse transcription and polymerase chain reaction in ten normal reduction mammoplasty samples, nine breast tumours with high PR levels (> 100 fmol mg −1 protein) and eight breast tumours with low PR levels (< 15 fmol mg −1 protein), as determined by ligand binding assay. The relative expression of D6-PR to wild-type PR mRNA was lower ( P < 0.01) in normal than in all tumour breast samples. Moreover, a trend to lower ( P < 0.1) relative D6-PR expression was observed in high PR tumours, compared to low PR tumours. These data suggest that increased expression of D6-PR occurs during tumorigenesis. © 1999 Cancer Research Campaign

show abstract

Progesterone Receptors as a Prognostic Factor in Stage II Breast Cancer

Cited by 340 publications

References 5 publications

Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas

Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas

Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01)

Altered expression of exon 6 deleted progesterone receptor variant mRNA between normal human breast and breast tumour tissues

Contact Info

Product

Resources

About